Among the limited clinical evidence of advantages of CAR T cell-based therapy along with RT in hematological malignancies is a case report of a patient with refractory DLBCL who benefited from 5*4Gy fractions of RT prior to CD19 CAR T cell therapy given for largely CD19-negative disease. This evidence concerns the gene CD19 and hematologic disorder.